Journal of Clinical Oncology
Articles in this Issue
Burden of non-Hodgkin lymphoma in South Asia, 1990–2023: Analysis of the Global Burden of Disease study 2023.
e19086 Background: Non-Hodgkin lymphoma (NHL) contributes substantially to the global cancer burden, yet long-term, sex-sp...
Discovery of novel biomarkers for glioblastoma using VHH antibodies.
e14068 Background: Although comprehensive genomic profiling has revealed the molecular features of glioblastoma (GBM), mos...
Digital prehabilitation and functional performance signals in older adults undergoing hepatobiliary cancer surgery: A pilot study.
12039 Background: Older adults undergoing hepatobiliary cancer surgery often have limited functional reserve and face barr...
The impact of aspirin use on pathological outcomes in locally advanced rectal cancer patients undergoing total neoadjuvant therapy: Real-world data from the Ankara University Colorectal Cancer study group.
e15657 Background: Total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) has become standard of care, b...
Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1–positive non–small cell lung cancer (NSCLC) in AdvanTIG-105.
2571 Background: OCI (anti-TIGIT) plus TIS (anti-PD-1) may enhance antitumor immune responses in advanced solid tumors. We...
Evaluating the cost per month of response for olutasidenib (OLU) versus ivosidenib (IVO) for patients with relapsed/refractory (R/R) mutant <i>IDH1</i> (m <i>IDH1</i> ) acute myeloid leukemia (AML).
e18504 Background: In the United States (US), the incidence of AML has steadily increased over the past decade and is asso...
PAXG versus (m)FOLFIRINOX as first-Line therapy for unresectable locally advanced or metastatic pancreatic cancer: A real-world, propensity-weighted analysis.
e16401 Background: The PACT-21 (CASSANDRA) study recently demonstrated an event-free survival benefit with PAXG (cisplatin...
A phase I study of [225Ac]Ac-PSMA-XT, a novel alpha-particle–emitting radioligand therapy, in patients with metastatic castration-resistant prostate cancer.
5063 Background: Targeted alpha therapy (TAT) is an emerging modality for metastatic castration-resistant prostate cancer...
High mortality following unplanned breast cancer hospitalizations.
e23408 Background: The majority of breast cancer care occurs in outpatient settings, and data derived from hospital admiss...
Efficacy and safety of third-line treatments in metastatic colorectal cancer: A meta-analysis.
e15623 Background: Metastatic colorectal cancer (mCRC) in the third-line setting has limited options after progression on...
[ <sup>18</sup> F] Fluoroestradiol PET/CT to guide second-line treatment decision-making in patients with estrogen receptor–positive, HER2-negative advanced breast cancer after progression on first-line aromatase inhibitor and CDK4/6 inhibitor: Primary results of ESTROTIMP.
1077 Background: Despite availability of novel endocrine treatment (ET) options for patients with ER+ HER2- ABC, many pati...
Risk factors associated with early-onset versus later-onset pancreatic cancer: A systematic review and meta-analysis.
e16487 Background: The incidence of early-onset pancreatic cancer (EOPC), predominantly pancreatic ductal adenocarcinoma,...
Shallow whole-genome sequencing genomic instability score across endometrial cancer subtypes.
e17632 Background: Genomic instability (GI) is a hallmark of cancer. In endometrial cancer (EC) the TCGA molecular classif...
Comparative survival and long-term gastrointestinal outcomes of ipilimumab/nivolumab vs durvalumab/tremelimumab in unresectable hepatocellular carcinoma: A propensity-matched real-world analysis.
e16221 Background: The FDA approval of Nivolumab plus Ipilimumab (Ipi/Nivo) as a first-line (1L) therapy for unresectable...
Phase angle and urea-to-creatinine ratio in hospitalized cancer patients.
e24056 Background: Malnutrition, impaired cellular integrity, and hypercatabolic states are common in hospitalized cancer...
Financial toxicity and head and neck cancer: A systematic review and meta-analysis.
e13629 Background: Patients with head and neck cancer (HNC) may be particularly vulnerable to Financial Toxicity (FT) due...
Investigating transcriptional regulation of cisplatin sensitivity in small cell lung cancer using a functional overexpression screen.
e20162 Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy characterized by initial...
A phase 1/2 study of BDC-4182, a Claudin 18.2–targeting next-generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer.
TPS4242 Background: Claudin 18.2 (CLDN18.2) is a transmembrane tight junction protein with expression restricted to the ga...
Pharmacologic prevention of radiotherapy-induced nausea and vomiting: Network meta-analysis including olanzapine-based regimens.
e24087 Background: Radiotherapy-induced nausea and vomiting (RINV) negatively impacts adherence and quality of life. Multi...
Impact of adjuvant immunotherapy after pathologic complete response to neoadjuvant chemo-immunotherapy in resected stage II–III non–small cell lung cancer.
8062 Background: Perioperative chemo-immunotherapy has recently emerged as a new standard of care for patients with resect...
Artificial intelligence vs human-based frameworks for breast cancer molecular biomarker status assessment: A benchmarking analysis from 2500 patients.
e12568 Background: Accurate assessment of breast cancer biomarkers (HR-ER/PR, HER2, Ki-67 index) is essential for prognost...
Performance of a multi-cancer early detection test (MCED) for detecting small hepatocellular carcinoma (HCC) in a screening population.
4168 Background: Early diagnosis of small HCC (defined as single nodule ≤ 3 cm) is crucial, as it represents the optimal w...
Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
7059 Background: Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy that is often managed with chemoimmunot...
The great mismatch: Assessing cancer clinical trial accrual rates.
e23151 Background: Efforts to increase cancer clinical trial accruals have been disappointing. Much focus has been placed...
Clinical and molecular features of patients with <i>PIK3CA</i> -mutant ( <i>PIK3CA</i> m) ER+/HER2− breast cancer with detectable circulating tumor DNA (ctDNA) in early breast cancer (eBC).
e12609 Background: We previously reported that ~35% of ER+/HER2- eBC patients with a ctDNA-positive (ctDNA+) test result a...